Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLQ02 topical cyclosporine A for plaque psoriasis
NL-OMON51426Phase 1Active, not recruiting
- Sponsor
- Dermaliq Therapeutics, Inc.
- Start
- Jul 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DLQ02 and cyclosporine in plaque psoriasis (3 arms), sponsored by Dermaliq Therapeutics, Inc. Primary endpoints: Adverse events, Laboratory safety testing and 6 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
DLQ02cyclosporine
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON51426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51426.